41P - The in vitro and in vivo effects of mesenchymal stem cells on breast cancer cells

Date 04 May 2017
Event IMPAKT 2017
Session Welcome reception and Poster Walk
Topics Breast Cancer
Pathology/Molecular Biology
Basic Scientific Principles
Presenter Tetiana Herheliuk
Authors T. Herheliuk1, O. Perepelytsina1, O. Yakymchuk1, L. Ostapchenko2, M. Sydorenko1
  • 1Depatrtment Of Biotechnical Problems Of Diagnostics, Institute of Cryobiology and Cryomedicine of NAS of Ukraine, 03028 - Kiev/UA
  • 2Educational And Scientific Centre, Institute of Biology and Medicine, 03187 - Kiev/UA



Background. Bone marrow mesenchymal stem cells (BM-MSCs) are widely used in oncology, due to their ability to influence on inflammation, cell survival and migration. But effect of BM-MSCs on tumor cells is contradictory. MSCs can stimulate and inhibit the tumor process, depending on the components of the microenvironment, genesis and stage of differentiation. The aim of this study was to characterize the influence of biologically active substances from human bone marrow mesenchymal stem cells (hBM-MSCs) on proliferation, survival, receptor profile of MCF-7 in vitro and to analyze effect of mouse bone marrow mesenchymal stem cells (mBM-MSCs) on development of Ehrlich` carcinoma in vivo.

Methods. MCF-7 cell line (breast adenocarcinoma) was chosen as an experimental model in vitro. Laboratory mice Balb/2c, which grafted intramuscularly by EAC cells (Ehrlich`s ascites carcinoma), were chosen as a model in vivo. hBM-MSCs were cultured with multicellular spheroids MCF-7 (3D-culture) by non-contact method. mBM-MSCs were isolated from the thigh bone. Cell suspension (107 cells / ml in PBS) was stored at -200C. The cell cytosol was prepared slow thawing of suspension, and then it was injected to EAC mice every 4 days into the abdominal cavity (106 cells / 1mice). Cell viability was evaluated by MTT assay. Detection of markers was performed using IHC method with primary monoclonal antibodies Cks (clone AE1/AE3, Dako, USA), PanCks 5/6/8/18 (clone 5D3 and LP34, Dako, USA), ER α (clone EP1, Dako, USA), EGFR (Dako, USA), E-cadherin (Dako, USA).

Results. Our results demonstrate that hBM-MSCs have significant cytostatic effect on tumor populations. hBM-MSCs inhibited migration tumor cells to suspention by 50-60% compared with the control. After cocultivation of MCF-7 cells with hBM-MSCs proliferative activity was decreased by 2 times and the ability to migrate in the suspension fraction was reduced by 3.8 times. C-medium from hBM-MSCs reduces the volume of spheroids by 61% compared with the control. The rate of growth of the primary tumor was reduced after the injection of mBM-MSCs cytosol. Disposable injection of mBM-MSC inhibited tumor growth by 13%. Following injection of mBM-MSCs inhibited tumor growth by 31%.

Clinical trial identification